Long-term safety study of SD-101 in epidermolysis bullosa
Part of Genetic & congenital, Skin clinical trials.
This study is a safety follow-up for people who already completed the SD-007 trial. It gives everyone SD-101, an experimental treatment for epidermolysis bullosa, to see how well it works over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the earlier SD-007 study.
- You (or your caregiver) must be willing to follow all study rules.
- If you are able to become pregnant, you must not be pregnant, not breastfeeding, and use a highly effective birth control method (like birth control pills, an IUD, or complete abstinence).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This trial tests a skin cell treatment called pz-cel (made from your own cells) for people with a severe skin condition called dystrophic epidermolysis bullosa (DEB). It aims to help heal wounds by applying specially grown skin sheets.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
This study looks at long-term outcomes for people with recessive dystrophic epidermolysis bullosa (RDEB) who were previously treated with EB-101. It may help doctors understand how the treatment affects patients over time.
This trial tests a gel called oleogel-S10 on wounds caused by a rare skin condition called epidermolysis bullosa (EB). It is only for people of Japanese descent who have a specific type of EB called junctional or dystrophic EB. The gel is put on the wound to help it heal.
Hear when a new Epidermolysis Bullosa (EB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.